Press releases

Year: All
  • All

2021


July 16, 2021
IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam


July 15, 2021 Regulatory
Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease


June 15, 2021
IRLAB’s drug candidate pirepemat’s Phase I data published in scientific journal CPDD


June 2, 2021
IRLAB announces that equity research company Edison initiates coverage of the company


May 25, 2021
IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P


May 6, 2021 Regulatory
Report from the annual general meeting of IRLAB Therapeutics AB


May 6, 2021 Regulatory
IRLAB interim report January – March 2021


May 5, 2021
IRLAB publishes recorded speech and company presentation prior to digital AGM


April 15, 2021 Regulatory
IRLAB’s annual report for 2020 is now available on the company’s website


April 8, 2021 Regulatory
IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal


March 25, 2021
IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists


March 9, 2021
First European patients dosed in IRLAB’s Phase IIb/III mesdopetam study


February 24, 2021 Regulatory
IRLAB’s Year-end report January 1 – December 31, 2020


January 29, 2021 Regulatory
IRLAB announces change in share capital and number of shares following registered directed share issue


January 12, 2021
IRLAB presents application of deep learning on multidimensional CNS drug efficacy data


January 11, 2021
IRLAB presents new data indicating that mesdopetam could prevent dyskinesia in Parkinson’s Disease




2020


December 18, 2020 Regulatory
IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000


December 8, 2020
IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam


November 4, 2020
IRLAB starts Phase IIb/III study with mesdopetam in the US


October 30, 2020 Regulatory
Nomination committee in IRLAB appointed ahead of annual general meeting 2021


October 1, 2020 Regulatory
IRLAB’s mesdopetam IND accepted by the US FDA


September 30, 2020 Regulatory
IRLAB’s shares are now traded on Nasdaq Stockholm Main Market


September 25, 2020 Regulatory
IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market


September 23, 2020 Regulatory
IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market


September 10, 2020
IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET


August 3, 2020
IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO


July 9, 2020
IRLAB’s clinical drug candidate IRL752 published in JPET


June 24, 2020
IRLAB’s mesdopetam featured on cover of top-tier publication JPET


June 4, 2020
IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON


May 7, 2020 Regulatory
Report from the Annual General Meeting of IRLAB Therapeutics AB


May 6, 2020
IRLAB’s clinical drug candidate mesdopetam published in JPET


April 7, 2020 Regulatory
IRLAB publishes the annual report for 2019


March 23, 2020
IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders


February 27, 2020 Regulatory
IRLAB’s rights issue oversubscribed


February 7, 2020 Regulatory
IRLAB publishes prospectus relating to the rights issue


February 6, 2020 Regulatory
IRLAB launches new website


February 4, 2020
IRLAB’s IRL790 receives new name ‘mesdopetam’




2019


December 12, 2019 Regulatory
IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million


December 12, 2019 Regulatory
IRLAB intends to make a capital raise of approximately SEK 215 million


November 6, 2019
IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe


October 21, 2019
IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference


October 17, 2019 Regulatory
Nomination committee in IRLAB appointed


September 26, 2019 Regulatory
IRLAB’s IRL790 is proposed a unique INN by WHO


September 23, 2019
IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders


August 28, 2019
IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results


July 16, 2019
IRLAB reports top line results from Phase IIa study with IRL790


May 28, 2019
IRLAB and research consortium awarded MSEK 2.9 Vinnova grant


May 27, 2019 Regulatory
Today, May 27, is the last day of trading in IRLAB’s share before share split


May 17, 2019 Regulatory
IRLAB announces share split


May 9, 2019
IRLAB completes recruitment for its Phase II study with IRL790 in Parkinson’s disease patients with dyskinesia


April 25, 2019 Regulatory
IRLAB – Resolutions at Annual General Meeting 2019


April 3, 2019 Regulatory
IRLAB Therapeutics AB publishes annual report for 2018


March 14, 2019
IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review




2018




2017